



# Impact of a Collaborative Small Bowel Obstruction Imaging and Care Protocol with the General Surgery Service on Radiology Workflow and Resource Utilization

Kaitlin M. Zaki-Metias, MD<sup>1,2</sup>, Mark Glover, DO<sup>3</sup>, Trevena Metias, BSc<sup>4</sup>, Nathaniel Sertu, BSc<sup>4</sup>, Amy Braddock, MD<sup>3</sup>, Bashir H. Hakim, MD<sup>1,5</sup>, Stephen M. Seedial, MD, RPVI<sup>1,5</sup>

1. Department of Radiology, Trinity Health Oakland Hospital/Wayne State University School of Medicine, Pontiac, MI, USA
2. Department of Medical Imaging, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
3. Department of Surgery, Trinity Health Oakland Hospital/Wayne State University School of Medicine, Pontiac, MI, USA
4. Ross University School of Medicine, Bridgetown, Barbados
5. Huron Valley Radiology, Ypsilanti, MI, USA

[kaitlin.zaki-metias@lhsc.on.ca](mailto:kaitlin.zaki-metias@lhsc.on.ca)




# Background

- Small bowel obstruction (SBO) is a common cause of diagnostic imaging, hospital admission, and surgical consultation
  - SBO accounts for up to 16% of hospital admissions for abdominal pain
- Water-soluble contrast challenge (WSCC) has been implemented by surgical services to aid in differentiation between partial or low-grade SBO from complete or high-grade SBO
  - Abbreviated protocol comparable to fluoroscopic small bowel follow-through using serial static radiographs
  - Can be obtained in the radiology department or via portable radiography
  - Involves administration of enteric water-soluble contrast (orally or via nasogastric tube) with consecutive abdominal radiographs to follow the progression of contrast to the colon (timing of radiographs can vary by institution)
  - Transit time threshold for contrast to reach the colon of 24 hours
- WSCC can aid in determining the likelihood of successful nonoperative management in patients with SBO
- Gastrografin® is a water-soluble oral contrast agent often used in WSCC
- Surgical intervention is often indicated if WSCC is unsuccessful (transit time to colon > 24 hours)
- The use of Gastrografin® for WSCC has been shown to:
  - Decrease length of stay and decrease the one-year mortality rate when administered within 12 hours of hospitalization
  - Reduce cost of hospitalization in patients with SBO

# Background - Protocol

- Patients with suspected SBO often undergo initial CT imaging without oral contrast
  - Prior to the new protocol, it was usual for a second CT with oral contrast to be performed at our institution to confirm the diagnosis of SBO and guide further management
- A new institutional SBO care protocol was created by the general surgery service in collaboration with the radiology department
  - The new protocol eliminates the second CT, using oral water-soluble contrast material (Gastrografin®) and serial abdominal radiographs for further assessment in clinically stable patients



**Figure 1.** Institutional care algorithm for the management of small bowel obstruction (SBO).

# Background - Protocol

**Figure 2.** CT of the abdomen and pelvis without oral contrast (A) shows dilated fluid-filled small bowel loops in the left lower abdomen consistent with SBO. Frontal abdominal radiograph 4 hours after the administration of water-soluble contrast shows persistent mild small bowel dilatation with passage of contrast into the colon, excluding high-grade obstruction.



# Objective

- The purpose of this study is to assess the impact of this new institutional SBO care protocol and imaging algorithm on the radiology department's workflow and resource utilization

# Methods

Single-institution retrospective cohort study conducted on patients from the emergency department with SBO as diagnosed initial abdominopelvic CT and for whom the general surgery service was consulted.

## Study subjects:

- Control group:
  - Patients who underwent two consecutive abdominopelvic CT scans for SBO within 24 hours
    - One with oral contrast and one without oral contrast
  - One year prior to implementation of the new protocol (February 2022 - February 2023)
- Experimental group:
  - Patients who underwent imaging for suspected SBO per the new care and imaging algorithm (February 2023 - December 2023)

## Outcomes assessed


- Ionizing radiation exposure (effective dose)
- CT scanner/technologist time (based on technologist charting in electronic medical record)
- Contrast media utilization
- Operative vs nonoperative management
- Length of stay

# Results


Experimental group: 18 patients

Control group: 38 patients

- Total effective dose (mSv) was significantly less in the experimental group (mean 8.3 mSv  $\pm$  6.3 mSv) relative to the control group (mean 16.3 mSv  $\pm$  9.3 mSv) ( $p=0.02$ )




- Total CT time was significantly less in the experimental group (mean 12.7 minutes  $\pm$  3.9) relative to the control group (mean 28.4 minutes  $\pm$  14.8) ( $p<0.001$ )



# Results

- There was a trend for less use of intravenous contrast media in the experimental group relative to the control group, however, this was not statistically significant ( $p=0.06$ )



- Operative versus nonoperative management and length of stay were not significantly different between the two groups ( $p=1.0$  and  $p=0.517$ , respectively)

# Conclusion

- Implementation of a collaborative SBO imaging and care algorithm resulted in reduced effective dose to patients and decreased CT scanner/technologist time
- Potential for improved efficiency in CT department given less repeat CT scans for suspected or confirmed SBO in the absence of complications

# References

1. Cohen RB, Olafson SN, Krupp J, et al. Timing of Gastrografin administration in the management of adhesive small bowel obstruction (ASBO): Does it matter?. *Surgery*. 2021;170(2):596-602. doi:10.1016/j.surg.2021.03.008
2. Ali M, Slack DR, Feinn R, Kurtzman S, Zhang ZJ. Early Use of Small Bowel Follow Through Reduces Stay and Cost in Small Bowel Obstructions. *Cureus*. 2021;13(5):e15023. Published 2021 May 14. doi:10.7759/cureus.15023
3. Nelms DW, Kann BR. Imaging Modalities for Evaluation of Intestinal Obstruction. *Clin Colon Rectal Surg*. 2021;34(4):205-218. doi:10.1055/s-0041-1729737
4. Alnachoukati O, Ray-Zack M, Godin S, Apodaca T, Zielinski M, Dunn J. Optimal Timing of First Abdominal Radiography after Gastrografin Administration for Small Bowel Obstruction. *J Surg Res*. 2020;256:193-197. doi:10.1016/j.jss.2020.06.053
5. Almafreji I, Chinaka U, Hussain A, Lynch M, Cottrell R. Role of Gastrografin in Patients With Small Bowel Obstruction. *Cureus*. 2020;12(8):e9695. Published 2020 Aug 12. doi:10.7759/cureus.9695
6. Feister K, Konstantinoff K, Hamade M, Mellnick V. Pearls and Pitfalls of Imaging Small Bowel Obstruction. *Can Assoc Radiol J*. Published online February 27, 2024. doi:10.1177/08465371241230276